GlassScriptPhysician profile
Hong Cheng
NPI 1003050303
$983.98
in general payments reported to CMS, 2019-2025
10 companies · $264 in 2025
The $264 reported for 2025 was more than what 82% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2022: $229 · 2023: $233 · 2024: $72.84 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.29 | 2022-2023 | Ofev |
| Amgen INC. | $145.87 | 2025 | |
| Alexion Pharmaceuticals, INC. | $118.55 | 2025 | Ultomiris |
| Roche Diagnostics Corporation | $114.17 | 2019 | |
| Corcept Therapeutics | $107.92 | 2023 | Korlym |
| Gilead Sciences, INC. | $89.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $60.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $49.88 | 2022-2024 | Enhertu |
| Lilly USA, LLC | $41.71 | 2024 | |
| Merck Sharp & Dohme LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.